Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)
Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –
Biogen total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Biogen's total debt was $6.29B at Dec 31, 2025. For fiscal 2025 it was $6.29B, down 0.1% from the year before. Over ten years it grew 75.3% a year on average. The highest annual figure on record is $8.57B in fiscal 2021.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.29B | -0.1% |
| FY2024 | Dec 31, 2024 | $6.30B | -9.3% |
| FY2023 | Dec 31, 2023 | $6.94B | +10.5% |
| FY2022 | Dec 31, 2022 | $6.28B | -26.7% |
| FY2021 | Dec 31, 2021 | $8.57B | +14.2% |
| FY2020 | Dec 31, 2020 | $7.50B | +0.1% |
| FY2019 | Dec 31, 2019 | $7.50B | +24.9% |
| FY2018 | Dec 31, 2018 | $6.00B | +187400.0% |
| FY2017 | Dec 31, 2017 | $3.20M | -84.8% |
| FY2016 | Dec 31, 2016 | $21.10M | -7.9% |
| FY2015 | Dec 31, 2015 | $22.90M | +638.7% |
| FY2014 | Dec 31, 2014 | $3.10M | -99.5% |
| FY2013 | Dec 31, 2013 | $571.39M | -49.9% |
| FY2012 | Dec 31, 2012 | $1.14B | +7.5% |
| FY2011 | Dec 31, 2011 | $1.06B | -0.5% |
| FY2010 | Dec 31, 2010 | $1.07B | -1.3% |
| FY2009 | Dec 31, 2009 | $1.08B | -0.5% |
| FY2008 | Dec 31, 2008 | $1.09B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $6.29B | -26.6% |
| Q4 FY2024 | Dec 31, 2024 | $6.30B | -16.1% |
| Q4 FY2023 | Dec 31, 2023 | $6.94B | -7.4% |
| Q4 FY2022 | Dec 31, 2022 | $6.28B | +4.7% |
| Q4 FY2021 | Dec 31, 2021 | $8.57B | – |
| Q4 FY2020 | Dec 31, 2020 | $7.50B | – |
| Q4 FY2019 | Dec 31, 2019 | $7.50B | +227045.5% |
| Q4 FY2018 | Dec 31, 2018 | $6.00B | +187400.0% |
| Q3 FY2018 | Sep 30, 2018 | $0 | -100.0% |
| Q2 FY2018 | Jun 30, 2018 | $0 | -100.0% |
| Q1 FY2018 | Mar 31, 2018 | $3.30M | -99.4% |
| Q4 FY2017 | Dec 31, 2017 | $3.20M | -84.8% |
| Q3 FY2017 | Sep 30, 2017 | $573.20M | – |
| Q2 FY2017 | Jun 30, 2017 | $559.90M | – |
| Q1 FY2017 | Mar 31, 2017 | $561.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $21.10M | – |
See a number that looks wrong?